XianSheng Pharmaceuticals ( 02096.HK ) Subsidiary to acquire 100% equity of Shanghai XianSheng Diagnostic Technology for 30.76 million yuan

Gelonghui, March 25 - Sinopharm Group (02096.HK) announced that on March 25, 2026, the buyer, Sinopharm Group Co., Ltd. (an indirect wholly-owned subsidiary of the company), entered into a share transfer agreement with the seller, Jiangsu Sinopharm Diagnostic Technology Co., Ltd., under which the buyer agrees to acquire and the seller agrees to sell all equity of the target company, Shanghai Sinopharm Diagnostic Technology Co., Ltd., for a cash consideration of RMB 30.76 million.

The acquisition aims to create an open innovation exchange center (“Center”), which is an important strategic facility for implementing the innovation-driven development strategy. As a strategic facility, the Center will build an industrial incubation and transformation platform to expand and attract a group of high-potential innovative entities for collaboration. It will also develop supporting living facilities to meet the needs of talent recruitment, project cooperation, and academic exchanges both internally and externally.

The Center aims to create an innovative platform that gathers the group’s innovative resources and strengthens external interaction capabilities, promoting international industry partners to establish offices, facilitating the deep integration of global R&D resources with China’s life science innovation ecosystem. At the same time, a number of innovative projects will be introduced for incubation, undertaking forward-looking layouts to seize disruptive innovation opportunities. The Center is expected to significantly enhance the group’s external collaboration capabilities, thereby strengthening innovation upgrades and strategic adaptability.

Based on the need for continuous business expansion and enhancement of innovation capabilities, the group will continue to increase talent density, attract and reserve more outstanding talents, and establish a sound mechanism for selecting, employing, cultivating, and retaining high-level talents. Supporting living facilities are an important support for attracting high-end talents. Currently, the group’s existing living support resources have increasingly highlighted severe limitations in meeting future talent reserve needs. To overcome existing constraints, building centralized living support has become a strategically necessary measure.

The target land, due to its superior geographical location and compliance with planning uses, is regarded as an ideal site for the Center’s development. Its convenient transportation conditions and proximity to the group’s personnel and external partners will help optimize travel arrangements and establish a stable and sustainable communication hub. Since preliminary construction has already begun on the target land, compared to seeking a new site to start a new construction cycle, the acquisition can significantly shorten the Center’s completion timetable, avoid duplicated investments, and reduce project uncertainties. The target land’s location and the Center’s construction schedule are aligned with the group’s operational planning and strategic development goals, which will help support the group’s long-term growth and market competitiveness in an increasingly dynamic business environment.

Upon completion of the acquisition, the target company will become an indirect wholly-owned subsidiary of the company, and the target company’s financial performance will be consolidated into the group’s financial statements.